iTeos Therapeutics

To kick off the year, iTeos Therapeutics CEO Michel Detheux presented at #JPM25 last week to highlight what 2025 has in store for TIGIT and our emerging IO pipeline. As a company, we could not be more excited as we anticipate belrestotug + dostarlimab data from >400 patients in 2025 across three trials in 1L NSCLC and 1L HNSCC as well as advancing two new therapies with potential to be the next breakthroughs in IO. To learn more about our progress, strategic priorities, and milestones, click here -> https://lnkd.in/eYXiEHkT To listen to our presentation and Q&A session at the JPM Healthcare Conference, click here -> https://lnkd.in/eGGptuwX

As a Belgian biotech rooted in innovation and a spin-off of the Ludwig Cancer Research (LICR) and de Duve Institute (UCL), we are incredibly proud of how far we've come as a company in 2024. Looking ahead to an exciting 2025, we owe our success to the dedication of our brilliant team, to those that remind us of why our work is so important - like the incredible Stefanie Veraghtert - and the strength of our core values: Data Driven, Ownership, Courage, and Stronger Together. These principles have guided our journey and continue to shape our path forward. At the heart of our mission is a commitment to discovering and developing potential first- and best-in-class therapies that make a difference for patients. We could not be more excited for the opportunities ahead and remain focused on achieving meaningful milestones in 2025.

Today we announced our third quarter 2024 financial results and provided a business update. Key highlights include: ➡️ Belrestotug 400mg + dostarlimab was granted clearance by the EMA as the recommended Phase 3 dose, allowing us to start treating patients in the EU ➡️ 5 presentations (2 mini oral, 3 posters) on inupadenant and EOS-984 will be presented at ESMO IO on Thursday, December 12th, including clinical data from the Phase 2 A2A-005 trial in 2L NSCLC ➡️ Completed Phase 1 APT-008 enrollment of the EOS-984 monotherapy dose escalation ahead of schedule and started treating patients with the combination of EOS-984 + pembrolizumab To learn more about our 3Q earnings: https://lnkd.in/ecQ-hfRC

iTeos is pleased to announce that the interim data from A2A-005, the Phase 2 trial assessing inupadenant and platinum-doublet chemotherapy in post-immunotherapy, metastatic non-small cell lung cancer patients, will be featured with two mini oral presentations ESMO-IO Congress 2024! The Company will also be highlighting additional preclinical data from inupadenant and EOS-984 to further highlight their unique mechanisms of action during the poster session. To learn more about the timing of these presentations at ESMO-IO -> https://lnkd.in/ecCQG4zy #ESMOImmuno24 #Adenosine #NSCLC

iTeos Therapeutics relance l’intérêt pour de nouveaux traitements anticancéreux Une société belge de biotechnologie qui fait mieux que des poids lourds pharmaceutiques dans la lutte contre le cancer... C'est l'exploit qu'est en train de réaliser l'entreprise carolo iTeos Therapeutics! La biotech a publié les données cliniques sur son traitement contre le cancer du poumon. De quoi relancer l'intérêt pour les médicaments basés sur la technologie anti-Tigit. "Ces résultats sont fantastiques. Ils ont été reçus comme une des trois meilleures nouvelles de la conférence. Certains analystes ont parlé d'une révolution dans ce domaine", se réjouit Michel Detheux, le CEO et président d'iTeos. ✍️ Un article de Olivier Gosset 👉 À lire ici https://lnkd.in/eavWqhci #cancer #poumon #biotech #pharma #santé #sciences

We are thrilled to announce the appointment of Michel Detheux, Ph.D, as Chairman of the Board. Michel Detheux brings an extensive experience in building and leading innovative entrepreneurial biotechnology companies in #tumorimmunology and #tumormicroenvironment. His expertise in the field of oncology will be instrumental for us to successfully execute on our strategic priorities. #TREG #immuno #oncology Institut Curie EQT Life Sciences InnoBio Bpifrance Life Sciences Venture FundPlus Bioqube Ventures JDRF International Takeda Ventures, Inc.

As an exciting first for iTeos, this morning we presented a follow-up interim analysis from GALAXIES Lung-201 in the proffered paper NSCLC session at #ESMO2024 where we unveiled that our TIGIT:PD-1 doublet observed a clinically meaningful confirmed ORR of ~60% at every dose, a >30% cORR difference compared to dostarlimab monotherapy.  "With roughly 60% confirmed ORR at three distinct doses and a meaningful difference of 30% compared to dostarlimab alone, we believe this underscores the potential differentiation of our TIGIT:PD-1 doublet,” said Michel Detheux, Ph.D., president and chief executive officer of iTeos. To learn more about our presentation, click here -> https://lnkd.in/e5myHgR7 #TIGIT #NSCLC

BioSpace: Bispecific antibodies and anti-TIGIT therapies both appear to be writing comeback stories as cancer experts head to Barcelona for the 2024 European Society for Medical Oncology Congress. “I think TIGIT is one of the targets which could provide responses in some of the cancers that checkpoint therapies today have not been as effective in,” Omid Veiseh, a professor of bioengineering at Rice University and director of the Rice University Biotech Launch Pad, told BioSpace. A nice, succinct preview on anticipated presentations at #ESMO2024 by Heather McKenzie. We and GSK look forward to presenting an interim analysis of the Phase 2 GALAXIES LUNG-201 platform study in a proffered paper session at the upcoming ESMO 2024 congress on September 14, 2024 at 8:30AM CEST. #TIGIT #NSCLC

iTeos is thrilled to announce that the interim data from GALAXIES Lung-201, the Phase 2 platform study sponsored by iTeos’ development partner GSK, assessing the belrestotug + dostarlimab (TIGIT:PD-1) doublet in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer, will be presented as a late-breaking oral presentation at ESMO - European Society for Medical Oncology Congress 2024! Initial details about this interim dataset were announced in May 2024 ->  https://lnkd.in/ejTbwwHs To learn more about the timing of GALAXIES Lung-201 presentation at ESMO -> https://lnkd.in/ewFn4YWX #ESMO2024 #TIGIT #NSCLC

Today we announced our second quarter 2024 financial results and provided a business update. Learn more here: https://lnkd.in/exjCxQGg